FDA Accepts BLA for Pertuzumab Biosimilar in HER2+ Breast Cancer
The FDA has accepted for a review a biologics license application (BLA) seeking the approval of HLX11, an investigational biosimilar referencing pertuzumab (Perjeta), in the treatment of select patients with HER2-positive breast cancer.1 Pertuzumab is …